MAPK1 and hepatocellular carcinoma: After the treatment of doxorubicin, the viability of HCC cells decreased dramatically, accompanied by significantly down-regulation of Syncytin-1 expression level and the activity of the MEK/ERK pathway (Fig. 6a, b).